Dr. Brose Discusses Lenvatinib for the Treatment of Patients With Thyroid Cancer
Marcia S. Brose, MD, PhD, discusses the SELECT trial, which looks at lenvatinib for patients with 131I-refractory differentiated thyroid cancer.
Lenvatinib has been a very active agent both in the first-line setting and in patients previously treated with other agents, including ceritinib, says Brose.
In both cases, patients treated with lenvatinib are doing well and the response rate is very high. In a phase III trial, 63% of patients experienced a partial response, and a couple of complete responses were also reported.
Brose believes this is clinically significant, especially when patients have very aggressive or symptomatic disease.
Marcia S. Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery at the Hospital of the University of Pennsylvania, discusses the SELECT trial, which looks at lenvatinib for patients with131I-refractory differentiated thyroid cancer.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
